头孢吡肟-恩美唑巴坦:新型β-内酰胺/β-内酰胺酶抑制剂的药物综述。

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Cameron Lanier, Tyler Melton, Kelly Covert
{"title":"头孢吡肟-恩美唑巴坦:新型β-内酰胺/β-内酰胺酶抑制剂的药物综述。","authors":"Cameron Lanier, Tyler Melton, Kelly Covert","doi":"10.1177/10600280241279904","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT).</p><p><strong>Data sources: </strong>A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: \"cefepime-enmetazobactam\" or \"cefepime\" or \"enmetazobactam\" or \"cefepime\" or \"novel beta-lactamase inhibitor\" and \"complicated urinary tract infection\" or \"cUTI.\" Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review.</p><p><strong>Study selection and data extraction: </strong>Relevant studies in English and clinical trials conducted in humans were reviewed.</p><p><strong>Data synthesis: </strong>In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam/beta-lactamase inhibitor (BL/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]).</p><p><strong>Relevance to patient care and clinical practice in comparison to existing agents: </strong>This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL/BLI combinations including utility in drug-resistant infections.</p><p><strong>Conclusions: </strong>FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280241279904"},"PeriodicalIF":2.3000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor.\",\"authors\":\"Cameron Lanier, Tyler Melton, Kelly Covert\",\"doi\":\"10.1177/10600280241279904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT).</p><p><strong>Data sources: </strong>A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: \\\"cefepime-enmetazobactam\\\" or \\\"cefepime\\\" or \\\"enmetazobactam\\\" or \\\"cefepime\\\" or \\\"novel beta-lactamase inhibitor\\\" and \\\"complicated urinary tract infection\\\" or \\\"cUTI.\\\" Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review.</p><p><strong>Study selection and data extraction: </strong>Relevant studies in English and clinical trials conducted in humans were reviewed.</p><p><strong>Data synthesis: </strong>In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam/beta-lactamase inhibitor (BL/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]).</p><p><strong>Relevance to patient care and clinical practice in comparison to existing agents: </strong>This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL/BLI combinations including utility in drug-resistant infections.</p><p><strong>Conclusions: </strong>FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.</p>\",\"PeriodicalId\":7933,\"journal\":{\"name\":\"Annals of Pharmacotherapy\",\"volume\":\" \",\"pages\":\"10600280241279904\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10600280241279904\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280241279904","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的描述并分析头孢吡肟-恩马唑巴坦(FEP-EMT)的药效学和药代动力学特性以及支持其疗效和使用的临床证据:使用 MEDLINE 和 EMBASE 数据库(2015 年 1 月至 2024 年 5 月)进行文献检索。检索词包括"头孢吡肟-恩美唑巴坦 "或 "头孢吡肟 "或 "恩美唑巴坦 "或 "头孢吡肟 "或 "新型β-内酰胺酶抑制剂 "以及 "复杂性尿路感染 "或 "cUTI"。会议摘要、参考书目、临床试验和药物专著均纳入审查范围:研究选择和数据提取:对相关的英文研究和人体临床试验进行了综述:2024年2月,美国食品和药物管理局(FDA)批准了β-内酰胺/β-内酰胺酶抑制剂(BL/BLI)复方制剂FEP-EMT用于治疗复杂性尿路感染(cUTI)和急性肾盂肾炎,在此之前,将其与哌拉西林-他唑巴坦(TZP)进行比较的III期ALLIUM试验已经完成。试验结果显示,在临床治愈和微生物根除的主要结果上,FEP-EMT 组达到 79.1%,而 TZP 组为 58.9%(95% CI 21.2 [14.3 至 27.9]):本综述介绍了 FEP-EMT 用于治疗 cUTI 的情况,并将其与其他新型 BL/BLI 组合药物进行了比较,包括在耐药感染中的应用:结论:FEP-EMT 为减少碳青霉烯类药物在广谱β-内酰胺酶(ESBL)产生的肠杆菌科细菌中的过度使用提供了一种抗菌选择。然而,与其他新型BL/BLI复方制剂不同的是,FEP-EMT对较难治疗的病原体的抗菌谱有限,而且成本也可能影响其总体使用率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor.

Objective: To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT).

Data sources: A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: "cefepime-enmetazobactam" or "cefepime" or "enmetazobactam" or "cefepime" or "novel beta-lactamase inhibitor" and "complicated urinary tract infection" or "cUTI." Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review.

Study selection and data extraction: Relevant studies in English and clinical trials conducted in humans were reviewed.

Data synthesis: In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam/beta-lactamase inhibitor (BL/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]).

Relevance to patient care and clinical practice in comparison to existing agents: This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL/BLI combinations including utility in drug-resistant infections.

Conclusions: FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
166
审稿时长
3-8 weeks
期刊介绍: Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信